ADVANCED SOLID TUMOR

This study tested a combination of two drugs, mirdametinib and BGB-3245, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drugs could shrink tumors. The study was terminated early, so resul…

This study tested an experimental drug (serabelisib) combined with a low-insulin diet, with or without chemotherapy, in adults with advanced solid tumors that have specific genetic changes (PIK3CA mutations). The goal was to see if the diet could reduce side effects and improve t…

This early-phase trial tested a new drug called RP-3467, alone or combined with olaparib, in 26 adults with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so results…

This study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed. The goal was to check safety, side effects, and whether the drug could shrink tumors. The trial was stopped early, so results are limited.

This early-stage study tested a new drug called DCC-3116, alone or with other targeted therapies, in people with advanced solid tumors that have certain gene mutations (RAS/MAPK pathway). The trial was terminated early, so results are limited. It involved 91 participants and aime…

This study tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors like colorectal, nasopharyngeal, and lung cancer. The goal was to find a safe dose and see if the combo could control the disease. The trial was terminated early, so re…

This early-phase study tested a new treatment called VAXINIA (a virus designed to attack cancer cells) in 66 adults with advanced solid tumors that had spread. The virus was given alone or with an immunotherapy drug (pembrolizumab), either as a shot into the tumor or through an I…

This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…

This early-stage study tested a new drug called M9466 combined with chemotherapy for people with advanced solid tumors, including colorectal cancer. The main goal was to check safety and find the right dose. The study was stopped early and only enrolled 3 participants, so no stro…

This study tested a new drug (PRT3789) combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific genetic change called SMARCA4 mutation. The goal was to see if the combination was safe and could shrink tumors. The study was terminate…

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors (like lung or stomach cancer) that have a specific genetic change called SMARCA4. The main goals were to check safety, find the right dose, and see if the drug shrinks tumo…

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The goal was to see if the drug could shrink tumors. The trial was terminated early, so results are limited. Participants had to have stopped…

This early-stage study tested an experimental oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, and results ar…

This early-stage study tested a new drug called BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped ear…

This early-stage study tested an experimental drug called RiMO-401, injected directly into tumors, combined with radiation therapy. It involved 5 adults with advanced solid cancers that could not be cured. The main goal was to find a safe dose and check for side effects.

This study tested a new drug called JSKN033 in 11 people with advanced solid tumors that have a protein called HER2. The goal was to see if the drug is safe and what dose works best. The trial was stopped early, so results are limited.

This early-stage trial aimed to test the safety of combining two cancer drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific KRAS G12C mutation. The study focused on certain cancers like gynecological, breast, pancreatic, and a type of lung can…

This early-stage study tested a new drug (RP-6306) combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors, including colorectal, GI, and esophageal cancers that had stopped responding to other treatments. The main goals were to check safety, find th…

This early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had no standard treatment options. The main goals were to check the drug's safety and how the body processes it. The trial was terminated early, so results are limited.

This early-stage trial tested a new drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have specific genetic changes (MAPK pathway). The study was stopped early, so results are limited. The goal was to find safe doses and see…

This early-stage study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited and no clear benefit…

This study tested an experimental drug called TransCon TLR7/8 Agonist, given as an injection into tumors, either alone or with another drug (pembrolizumab). It aimed to find a safe dose and check for side effects in people with advanced solid tumors that had stopped responding to…

This early-phase study tested a new drug called PHN-010 in 26 people with advanced solid tumors (lung, colon, endometrial, ovarian, or cervical cancer) that had already been treated with at least one prior therapy. The drug is an antibody-drug conjugate designed to deliver a toxi…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors (like lung or colon cancer) that have specific KRAS gene mutations. The main goals were to check safety and find the right dose. The study was…

This study tested a personalized treatment called TIL therapy for people with advanced solid tumors. Doctors took immune cells from the patient's own tumor, grew them in a lab, and then put them back into the patient to attack the cancer. The goal was to see if this approach is s…

This early-stage study tested a new drug, BGB-B3227, alone or with another drug (tislelizumab) in 35 people with advanced solid tumors. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested a new drug called NUV-868, alone or combined with other cancer drugs (olaparib or enzalutamide), in people with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The study was…

This study tested a combination of two drugs, SON-1010 and atezolizumab, in people with advanced solid tumors and platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow cancer growth. The study was terminated early, so results are limite…

This early-stage study tested a new drug called BRY805 in 13 people with advanced solid tumors who had no other treatment options. The main goal was to check the drug's safety and find the best dose. The study was terminated early, so results are limited.

This study aimed to see how a new drug (S095012) spreads through the body and targets tumors in people with advanced solid cancers. Only 3 people took part before the study was stopped early. The main goal was to use PET scans to track the drug, not to treat the cancer.